<DOC>
	<DOCNO>NCT00730132</DOCNO>
	<brief_summary>This study perform evaluate variant lipid-lowering therapy use Russian clinical practice coronary heart disease ( CHD ) patient hypercholesterolemia initial statin therapy achieve low density lipoprotein-cholesterol ( LDL-C ) goal . Additionally , efficacy safety variant modify lipid-lowering therapy evaluate .</brief_summary>
	<brief_title>Observational Study Approaches Lipid-Lowering Therapy Russian Patients With Coronary Heart Disease &lt; &lt; Treat Goal &gt; &gt; ( Study P05464 )</brief_title>
	<detailed_description>Given observational nature study assessment specific hypothesis foreseen , statistical assumption plan sample size calculation perform . Taking consideration available data establish safety profile therapy statins combination ezetimibe statin suggest sample size 750 patient sufficient identify adverse event profile . The treatment effect characterize descriptive frequency parameter .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male Female , 18 75 year old ; Established diagnosis CHD ; Previous ( least , within 1 month inclusion present study ) treatment statin ; Levels plasma TC LDLC recommend target value ( TC &gt; 4.5 mmol\L ; LDLC &gt; 2.5 mmol/L ) ; The write informed consent sign prior start participation study . Contraindications statin ezetimibe ( Ezetrol ) administration accordance local Russian Federation medical instruction . Patients refuse participate study and/or sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>